Adverum Biotechnologies Number Of Shares Shorted vs. Revenue

ADVM Stock  USD 5.89  0.04  0.68%   
Based on Adverum Biotechnologies' profitability indicators, Adverum Biotechnologies may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Adverum Biotechnologies' ability to earn profits and add value for shareholders. At this time, Adverum Biotechnologies' Days Sales Outstanding is very stable compared to the past year. As of the 11th of December 2024, Sales General And Administrative To Revenue is likely to grow to 17.94, while EV To Sales is likely to drop 23.05. As of the 11th of December 2024, Total Other Income Expense Net is likely to grow to about 5.8 M, while Accumulated Other Comprehensive Income is likely to drop (496.6 K).
For Adverum Biotechnologies profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Adverum Biotechnologies to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Adverum Biotechnologies utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Adverum Biotechnologies's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Adverum Biotechnologies over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adverum Biotechnologies. If investors know Adverum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adverum Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(5.95)
Revenue Per Share
0.059
Quarterly Revenue Growth
(0.70)
Return On Assets
(0.30)
Return On Equity
(0.76)
The market value of Adverum Biotechnologies is measured differently than its book value, which is the value of Adverum that is recorded on the company's balance sheet. Investors also form their own opinion of Adverum Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adverum Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adverum Biotechnologies' market value can be influenced by many factors that don't directly affect Adverum Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adverum Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adverum Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adverum Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Adverum Biotechnologies Revenue vs. Number Of Shares Shorted Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Adverum Biotechnologies's current stock value. Our valuation model uses many indicators to compare Adverum Biotechnologies value to that of its competitors to determine the firm's financial worth.
Adverum Biotechnologies is rated below average in number of shares shorted category among its peers. It is rated below average in revenue category among its peers totaling about  2.36  of Revenue per Number Of Shares Shorted. At this time, Adverum Biotechnologies' Total Revenue is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Adverum Biotechnologies by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Adverum Revenue vs. Number Of Shares Shorted

Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.

Adverum Biotechnologies

Shares Shorted

 = 

Shorted by Public

+

by Institutions

 = 
1.53 M
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Adverum Biotechnologies

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
3.6 M
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Adverum Revenue vs Competition

Adverum Biotechnologies is rated below average in revenue category among its peers. Market size based on revenue of Health Care industry is presently estimated at about 170.71 Million. Adverum Biotechnologies holds roughly 3.6 Million in revenue claiming about 2.11% of equities under Health Care industry.

Adverum Biotechnologies Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Adverum Biotechnologies, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Adverum Biotechnologies will eventually generate negative long term returns. The profitability progress is the general direction of Adverum Biotechnologies' change in net profit over the period of time. It can combine multiple indicators of Adverum Biotechnologies, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-473 K-496.6 K
Operating Income-123.8 M-130 M
Income Before Tax-118.2 M-124.2 M
Total Other Income Expense Net5.5 M5.8 M
Net Loss-117.2 M-123 M
Income Tax Expense-1.1 M-1 M
Net Loss-117.2 M-123 M
Non Operating Income Net Other177.1 K168.2 K
Net Loss-139.1 M-146 M
Change To Netincome18 M17.6 M
Net Loss(11.62)(12.20)
Income Quality 0.78  0.51 
Net Income Per E B T 0.99  0.80 

Adverum Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Adverum Biotechnologies. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Adverum Biotechnologies position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Adverum Biotechnologies' important profitability drivers and their relationship over time.

Use Adverum Biotechnologies in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adverum Biotechnologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adverum Biotechnologies will appreciate offsetting losses from the drop in the long position's value.

Adverum Biotechnologies Pair Trading

Adverum Biotechnologies Pair Trading Analysis

The ability to find closely correlated positions to Adverum Biotechnologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adverum Biotechnologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adverum Biotechnologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adverum Biotechnologies to buy it.
The correlation of Adverum Biotechnologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adverum Biotechnologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adverum Biotechnologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Adverum Biotechnologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Adverum Biotechnologies position

In addition to having Adverum Biotechnologies in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Small Growth Funds Thematic Idea Now

Small Growth Funds
Small Growth Funds Theme
Funds or Etfs that invest in stocks of small to mid-sized companies with above-average risk and growth rate that usually reinvest their earnings back into business. The Small Growth Funds theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small Growth Funds Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Adverum Biotechnologies is a strong investment it is important to analyze Adverum Biotechnologies' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Adverum Biotechnologies' future performance. For an informed investment choice regarding Adverum Stock, refer to the following important reports:
Check out Trending Equities.
To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.
You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
To fully project Adverum Biotechnologies' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Adverum Biotechnologies at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Adverum Biotechnologies' income statement, its balance sheet, and the statement of cash flows.
Potential Adverum Biotechnologies investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Adverum Biotechnologies investors may work on each financial statement separately, they are all related. The changes in Adverum Biotechnologies's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Adverum Biotechnologies's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.